Abstract Number: 3100 • 2016 ACR/ARHP Annual Meeting
Can Achieving Sustained Minimal Disease Activity (MDA) Prevent Progression of Subclinical Atherosclerosis? a Prospective Cohort Study in Psoriatic Arthritis
Background/Purpose: Patients with PsA were reported to have a higher incidence of cardiovascular disease (CVD) and subclinical carotid atherosclerosis due to underlying inflammation. Minimal disease…Abstract Number: 1485 • 2016 ACR/ARHP Annual Meeting
Generation of New Carotid Plaque Is Determined By the Prexisting Carotid Atherosclerosis and Ongoning Disease Activity of Rheumatoid Arthritis
Background/Purpose: This study shows that carotid plaque at year 5 is predicted by IMT and dyslipidemia at baseline, whereas formation of new plaques after…Abstract Number: 3101 • 2016 ACR/ARHP Annual Meeting
Lipoprotein Profile and Serum Glycoprotein Acetylation As Markers of Cardiovascular Risk in Systemic Lupus Erythematosus
Background/Purpose: The risk of atherosclerotic cardiovascular disease (CVD) is significantly increased in systemic SLE compared to age and gender matched controls. The implementation of nuclear…Abstract Number: 1653 • 2016 ACR/ARHP Annual Meeting
Delineating the Effects of Rheumatoid Arthritis Pharmacotherapies on Vascular Inflammation: Rationale and Design of a Clinical Trial
Background/Purpose: Rheumatoid arthritis is associated with an excess cardiovascular disease (CVD) burden. Fewer CVD events associated with specific DMARD therapies have been reported; however, causal…Abstract Number: 3102 • 2016 ACR/ARHP Annual Meeting
Neutrophil Subsets, Arterial Inflammation, and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) show a striking increase in risk of atherosclerotic cardiovascular disease (CVD) not explained by Framingham risk, when compared…Abstract Number: 1663 • 2016 ACR/ARHP Annual Meeting
Assessment of Serum Calprotectin and Osteoprotegerin Levels in a Cohort of Spanish Patients with Axial Spondyloarthritis
Background/Purpose: Calprotectin is a protein involved in several cellular processes including immunomodulation1. Elevated levels of this protein have been observed in inflammatory diseases, since it…Abstract Number: 1676 • 2016 ACR/ARHP Annual Meeting
Methotrexate and Anti-Tumor Necrosis Treatment Improve Endothelial Function in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Background/Purpose: Inflammatory rheumatic diseases (IRDs) are associated with accelerated atherosclerosis, which progression is related to inflammation (1). One of the first stages in atherogenesis is…Abstract Number: 1682 • 2016 ACR/ARHP Annual Meeting
Tnfα Inhibitors Are Associated with Reduced Progression of Carotid Atherosclerotic Plaques By Ultrasound and an Improvement in Aortic Arch Vascular Inflammation By 18-FDG PET/CT in Psoriasis and Psoriatic Arthritis Patients – a Prospective Study from Two Cohorts
Background/Purpose: Psoriasis (PSO) and psoriatic arthritis (PsA) are chronic inflammatory diseases which are associated with increased cardiovascular (CV) diseases. Observational studies have found that TNFα…Abstract Number: 1770 • 2016 ACR/ARHP Annual Meeting
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the First 10 Years
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the first 10 years Background/Purpose: The Medical Outcome Survey Short Form…Abstract Number: 1786 • 2016 ACR/ARHP Annual Meeting
Long-Term Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus in a Large Case Control Cohort Study
Background/Purpose: Certain traditional and disease-related factors have been identified to accelerate atherosclerosis in systemic lupus erythematosus (SLE). Due to the lack of long-term prospective studies,…Abstract Number: 1790 • 2016 ACR/ARHP Annual Meeting
Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort
Background/Purpose: The annual accrual of comorbidities in patients with SLE is not well described. We report the annual occurrence of these features in an inception…Abstract Number: 738 • 2016 ACR/ARHP Annual Meeting
Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus
Background/Purpose: Premature atherosclerosis is one of the major complications of systemic lupus erythematosus (SLE). Preventing atherosclerosis is a key objective while monitoring patients with SLE.…Abstract Number: 2168 • 2016 ACR/ARHP Annual Meeting
Metabolic Syndrome, All Cause Mortality and Atherosclerotic Cardiovascular Disease in Rheumatic Diseases
Background/Purpose: all-cause and cardiovascular mortality and cardiovascular morbidity are reportedly increased in rheumatic diseases, both inflammatory and non-inflammatory. Few studies, however have addressed the impact…Abstract Number: 880 • 2016 ACR/ARHP Annual Meeting
Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?
Background/Purpose: A key unmet need in the monitoring of disease activity in large vessel vasculitides (LVV), i.e., giant cell arteritis (GCA) and Takayasu arteritis…Abstract Number: 2425 • 2016 ACR/ARHP Annual Meeting
The Vasculopathy of Juvenile Dermatomyositis (JDM); Evidence of Persistent Endothelial Injury, Hypercoagulability, Subclinical Inflammation and Increased Arterial Stiffness
Background/Purpose: Vasculopathy is considered central to the pathogenesis of Juvenile Dermatomyositis (JDM). The interplay between persistent JDM-vasculopathy, traditional cardiovascular risk factors, exposure to corticosteroids, and…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 17
- Next Page »